Skip to main content
ALK-Abelló logo

ALK-Abelló — Investor Relations & Filings

Ticker · ALK ISIN · DK0061802139 LEI · 529900SGCREUZCZ7P020 CO Manufacturing
Open in API
Filings indexed 1,210 across all filing types
Latest filing 2026-05-04 Earnings Release
Country DK Denmark
Listing CO ALK

About ALK-Abelló

https://www.alk.net

ALK-Abelló is a global, research-driven pharmaceutical company specializing in the prevention, diagnosis, and treatment of allergies. The company is a world leader in allergy immunotherapy (AIT), also known as allergy vaccination, which is a disease-modifying treatment that targets the underlying cause of the allergy rather than just the symptoms. Its portfolio includes a range of allergy treatments and services, with products such as injections, sublingual tablets, and emergency treatments for severe allergic reactions like anaphylaxis. With over a century of experience, ALK-Abelló focuses on developing pharmaceutical products to improve the quality of life for people with allergies globally.

Recent filings

Filing Released Lang Actions
ALK upgrades its full-year outlook
Earnings Release Classification · 95% confidence The document is a company announcement from ALK updating its financial expectations for the full year 2026, including revenue and EBIT margin guidance. It mentions the upcoming release of the first quarter financial report and an investor presentation with a live audiocast. The document is short (2574 characters) and primarily serves as a market update and notification of an upcoming earnings release and investor call. It does not contain actual financial statements or detailed financial data itself, nor is it a transcript of the call or presentation. Therefore, it is best classified as an Earnings Release (ER), which is the initial announcement of quarterly/periodical financial results and key highlights.
2026-05-04 Danish
ALK upgrades its full-year outlook
Capital/Financing Update Classification · 95% confidence The document is a company announcement from ALK-Abelló A/S about an upward revision of its full-year 2026 financial expectations, including revenue growth and EBIT margin. It mentions the upcoming release of the Q1 financial report and an investor presentation with a live audiocast. The document is short (3240 characters) and primarily serves as a notification of updated guidance and an invitation to a conference call. It does not contain actual financial statements or detailed financial data. It also references the upcoming quarterly report but does not include it. Therefore, this document is best classified as a Capital/Financing Update (CAP) because it updates investors on financial expectations and related events, rather than being a full financial report or earnings release.
2026-05-04 Danish
ALK upgrades its full-year outlook
Capital/Financing Update Classification · 95% confidence The document is a company release announcing an upgrade to the full-year financial outlook for 2026, including revised revenue growth and EBIT margin expectations. It references the upcoming Q1 report publication and an investor presentation and conference call scheduled for the same day. The document is relatively short (2356 characters) and serves as an announcement of updated guidance and event details rather than containing actual financial statements or detailed financial analysis. It does not contain the full quarterly report or earnings release data itself but rather informs about the outlook upgrade and related events. Therefore, it fits best as a Capital/Financing Update (CAP) since it updates financial outlook and guidance, which is a form of capital/financial update. It is not an Earnings Release (ER) because it does not present initial quarterly financial results, nor is it a Report Publication Announcement (RPA) because it does not merely announce the report's availability but also updates financial outlook. Hence, the classification is CAP with high confidence.
2026-05-04 English
ALK upgrades its full-year outlook
Capital/Financing Update Classification · 95% confidence The document is a short announcement (3098 characters) about ALK upgrading its full-year financial outlook for 2026. It mentions the upcoming Q1 report publication and an investor presentation and conference call scheduled for the same day. The text does not contain detailed financial statements or substantive financial data itself but rather provides an update on expectations and invites investors to a call and presentation. It also includes a link to a company release attachment. This fits the pattern of a Capital/Financing Update (CAP) as it provides updated financial guidance and outlook information. It is not a full Annual Report, Interim Report, or Earnings Release since it lacks detailed financial results. It is not a Report Publication Announcement (RPA) because it contains substantive updated financial outlook information rather than just announcing a report's release. Therefore, the best classification is Capital/Financing Update (CAP).
2026-05-04 English
ALK announces successful outcome of phase 2 trial with its tablet for treatment of peanut allergy demonstrating early onset of efficacy
Regulatory Filings Classification · 75% confidence The document is a company announcement (Selskabsmeddelelse) disclosing clinical Phase 2 trial results for a peanut allergy tablet and contains “intern viden” under EU market abuse rules. It is not an earnings release, interim or annual report, nor does it relate to board changes, dividends, financing, M&A, or governance. It is a stand‐alone regulatory disclosure of trial data, fitting the fallback category for miscellaneous regulatory announcements.
2026-04-20 Danish
ALK announces successful outcome of phase 2 trial with its tablet for treatment of peanut allergy demonstrating early onset of efficacy
Regulatory Filings Classification · 87% confidence The document is a press release announcing positive Phase 2 clinical trial results for ALK’s peanut allergy tablet. It contains no financial results, no shareholder votes, no board changes, and no regulatory form filings such as 10-K or interim reports. Instead, it is a general corporate announcement on product development, which does not fit any specific category. The appropriate fallback category for such miscellaneous corporate announcements is “Regulatory Filings” (RNS).
2026-04-20 Danish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.